[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, Mason DP, Rodriguez CP, Ives DI: Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol; 2009 Oct;4(10):1264-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
  • INTRODUCTION: Mature results are presented from a phase II trial of postoperative concurrent chemoradiotherapy in patients with poor-prognosis cancer of the esophagus and gastroesophageal junction after primary surgical resection.
  • Concurrent chemoradiotherapy was begun between 6 and 10 weeks after surgery and consisted of radiotherapy (1.8 Gy/d to a planned dose of 50.4-59.4 Gy), concurrent with two cycles of 5-fluorouracil (1000 mg/m/d) and cisplatin (20 mg/m/d), both given as 4-day continuous intravenous infusions during the first and fourth weeks of the radiation.
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Esophagogastric Junction / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668013.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Socinski MA, Scappaticci FA, Samant M, Kolb MM, Kozloff MF: Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol; 2010 Mar;5(3):354-60
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
  • INTRODUCTION: Bevacizumab (B) improves survival of patients with metastatic, nonsquamous non-small cell lung cancer.
  • Based on encouraging results from preclinical studies combining B with sunitinib (S), a phase II, randomized, open-label study (Study Assessing the Blockade of both VEGF Receptor and ligand to enhance Efficacy in Lung) was initiated to assess clinical outcomes of adding S to paclitaxel (P)/carboplatin (C) + B (PCB) for first-line treatment of locally advanced, metastatic, or recurrent nonsquamous non-small cell lung cancer.
  • Median treatment duration was 10.3 weeks for PCB and 6.0 weeks for PCB + S.
  • Thirty-five percent of patients on PCB + S required S dose reduction, 52% required S treatment interruption, and 59% discontinued S because of adverse events, most frequently hematologic events (neutropenia, thrombocytopenia, and leukopenia) and fatigue.
  • Survival data were limited by small sample sizes and limited treatment duration.
  • Overall survival was not mature at time of analysis: median 6.6 months for PCB + S and not reached for PCB.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Cohort Studies. Female. Humans. Indoles / administration & dosage. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Pyrroles / administration & dosage. Safety. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20032789.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


3. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol; 2008 Nov 1;26(31):5043-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
  • PURPOSE: Adjuvant chemotherapy for resected non-small-cell lung cancer (NSCLC) is now accepted on the basis of several randomized clinical trials (RCTs) that demonstrated improved survival.
  • Although there is strong evidence that adjuvant chemotherapy is effective in stages II and IIIA NSCLC, its utility in stage IB disease is unclear.
  • This report provides a mature analysis of Cancer and Leukemia Group B (CALGB) 9633, the only RCT designed specifically for stage IB NSCLC.
  • PATIENTS AND METHODS: Within 4 to 8 weeks of resection, patients were randomly assigned to adjuvant chemotherapy or observation.
  • Chemotherapy consisted of paclitaxel 200 mg/m(2) intravenously over 3 hours and carboplatin at an area under the curve dose of 6 mg/mL per minute intravenously over 45 to 60 minutes every 3 weeks for four cycles.
  • Grades 3 to 4 neutropenia were the predominant toxicity; there were no treatment-related deaths.
  • However, exploratory analysis demonstrated a significant survival difference in favor of adjuvant chemotherapy for patients who had tumors > or = 4 cm in diameter (HR, 0.69; CI, 0.48 to 0.99; P = .043).
  • CONCLUSION: Because a significant survival advantage was not observed across the entire cohort, adjuvant chemotherapy should not be considered standard care in stage IB NSCLC.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5506-18 [17954710.001]
  • [Cites] J Thorac Oncol. 2007 Aug;2(8):706-14 [17762336.001]
  • [Cites] Chest. 2002 May;121(5):1515-20 [12006437.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4285-91 [12409326.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3852-9 [15326195.001]
  • [Cites] Biometrics. 1979 Sep;35(3):549-56 [497341.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1860-70 [7543559.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):51-4 [9007122.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):190-6 [15625373.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13 Pt 2):5017s-5021s [16000606.001]
  • [Cites] Chest. 2005 Nov;128(5):3255-60 [16304270.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):955-60 [16550600.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):719-27 [16945766.001]
  • [Cites] Oncology (Williston Park). 2006 Nov;20(13):1651-63; discussion 1663-4, 1666, 1669-70 passim [17175743.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 6;99(11):847-57 [17551145.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):593-602 [17607114.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2300-1; author reply 2301-2 [19332712.001]
  • [CommentIn] J Clin Oncol. 2008 Nov 1;26(31):5014-7 [18809602.001]
  • [CommentIn] Future Oncol. 2009 Feb;5(1):19-22 [19243293.001]
  • (PMID = 18809614.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA08025; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2652093
  •  go-up   go-down


Advertisement
4. Ondrus D, Hornák M, Breza J, Mat'oska J, Schnorrer M, Belan V, Kausitz J: Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol; 2001;32(4):665-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
  • INTRODUCTION: The therapeutic procedures in the management of testicular cancer are determined by histological findings in the removed testis and by the extent of the disease at the time of diagnosis.
  • However, all advanced tumors could be treated by primary chemotherapy regardless of the histological findings.
  • When the diagnosis of advanced tumor is evident, it is possible to start the treatment without orchiectomy.
  • The aim of this study was to evaluate the advantages of neo-adjuvant chemotherapy with delayed orchiectomy in the management of advanced testicular cancer.
  • MATERIAL AND METHODS: A total of 36 patients with advanced germ cell testicular cancer underwent primary PVB or BEP chemotherapy without previous orchiectomy.
  • The patients were treated with cisplatin-containing combination chemotherapy.
  • Following completion of chemotherapy, orchiectomy was performed alone or simultaneously with retroperitoneal lymph node dissection (RPLND) and/or lung metastasectomy in cases with persistent residual mass.
  • Following orchiectomy the patients were regularly checked and in cases with viable malignant tumor found in the testis sequential chemotherapy was administered.
  • Similarly when the relapse of the disease was detected, the patients were treated with sequential chemotherapy.
  • RESULTS: Complete disappearance of metastases was observed in 12 patients following chemotherapy alone.
  • The viable tumor in the removed tissue was found in one patient.
  • Delayed orchiectomy was performed simultaneously with surgical removal of residual mass in the retroperitoneum in 24 patients and as a separate procedure in 12 patients who have been considered to be complete responders following chemotherapy alone.
  • Residual viable tumor in testicular specimen was found in three patients, necrotic or fibrotic tissue in 18, and mature teratoma in 15 patients.
  • Overall survival of the patients was 26/36 (72.7%) at mean of 56.9 months (range 7-145 months, median 50 months) since the start of the treatment.
  • CONCLUSIONS: In patients with advanced germ cell testicular cancer preference must be given to the early beginning of intensive chemotherapy without the need of tissue diagnosis of primary tumor that should be obtained by orchiectomy.
  • Benefit of this therapeutic approach is the timely management of acute abdominal and/or pulmonary symptoms of life-threatening distant metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Germinoma / drug therapy. Orchiectomy. Testicular Neoplasms / drug therapy. Vinblastine / therapeutic use
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm, Residual. Survival Rate. Teratoma / secondary. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1984 Sep;2(9):1025-7 [6088708.001]
  • [Cites] J Urol. 1983 Mar;129(3):522-3 [6834536.001]
  • [Cites] J Urol. 1996 Mar;155(3):952-4 [8583615.001]
  • [Cites] Br J Cancer. 1983 May;47(5):613-9 [6189504.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1018-24 [7842403.001]
  • [Cites] Ann Intern Med. 1977 Sep;87(3):293-8 [71004.001]
  • [Cites] J Urol. 1986 Dec;136(6):1221-3 [3022018.001]
  • (PMID = 11989561.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; PVB protocol
  •  go-up   go-down


5. Horvath LG, McCaughan BC, Stockle M, Boyer MJ: Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours. Intern Med J; 2002 Mar;32(3):79-83
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours.
  • BACKGROUND: Resection of residual post-chemotherapy pulmonary masses in patients with non-seminomatous germ cell tumours gives therapeutic benefit and prognostic information.
  • METHODS: The Germ Cell Database of the Sydney Cancer Centre was searched for all patients who had undergone excision of pulmonary metastases.
  • RESULTS: Between 1976 and 1999, 15 patients underwent a combined total of 19 thoracotomies for resection of residual tumour mass after cisplatin-based chemotherapy.
  • The primary tumour histology included mature teratoma in 47% (7 of 15) of patients.
  • Prior to chemotherapy, 73% (11 of 15) of patients had elevated serum levels of alpha-fetoprotein (median 180 ng/mL) and 60% (9 of 15) of patients had elevated beta-human chorionic gonadotropin (median 672 IU/L).
  • Pathology of residual pulmonary masses revealed necrosis alone in 37% (7 of 19) of procedures, mature teratoma alone in 32% (6 of 19) of procedures and viable tumour in 32% (6 of 19) of procedures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Neoplasm, Residual / drug therapy. Neoplasm, Residual / mortality. Neoplasm, Residual / surgery. Pneumonectomy / methods. Registries. Retrospective Studies. Survival Analysis. Thoracotomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11885847.001).
  • [ISSN] 1444-0903
  • [Journal-full-title] Internal medicine journal
  • [ISO-abbreviation] Intern Med J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


6. Pujol JL, Jacot W, Breton JL, Gervais R, Quantin X, Rebattu P: [Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?]. Rev Pneumol Clin; 2004 Nov;60(5 Pt 2):3S60-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
  • [Transliterated title] Les associations sans platine: une alternative aux chimiothérapies conventionnelles des cancers bronchiques non à petites cellules?
  • Chemotherapy of advanced non-small cell lung cancers is based on cisplatin, which prolongs survival.
  • However, the high toxicity of double-type combinations including cisplatin warrants the search for alternatives.
  • Several randomised trials, already published or presented with mature results, suggest that certain bitherapies with new cytostatic agents are an alternative to the classical cisplatin-based bitherapies.
  • The recent modifications in the guidelines of the American Association of Clinical Oncology take into account these recent results by admitting that "chemotherapy without cisplatin can be used as an alternative to the first-line platin-based chemotherapies".
  • This brief review of the literature underlines the methodological questions raised by the publication of randomised studies essentially assessing gemcitabine-vinorelbine or gemcitabine-taxane combinations, by confronting them with either mono-chemotherapies or reference chemotherapy based on cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives
  • [MeSH-minor] Humans. Neoplasm Staging. Paclitaxel / administration & dosage. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15536356.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  • [Number-of-references] 27
  •  go-up   go-down


7. Shimamura T, Shapiro GI: Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol; 2008 Jun;3(6 Suppl 2):S152-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock protein 90 inhibition in lung cancer.
  • The heat shock protein 90 (Hsp90) chaperone is required for the conformational maturation and stability of multiple oncogenic kinases that drive signal transduction and proliferation of lung cancer cells.
  • The recent demonstration that mutant epidermal growth factor receptor is an Hsp90 client, irrespective of the presence of the secondary threonine-to-methionine amino acid substitution mutation at position 790 mediating anilinoquinazoline resistance, suggests Hsp90 inhibition as a novel strategy against this group of lung cancers.
  • Lung cancers may also be driven by mutant ErbB2, mutant B-Raf, or mutant or overexpressed c-Met, all of which are also degraded on Hsp90 inhibition.
  • Hsp90 inhibitors may be synergistic with other drugs that disrupt chaperone function, including inhibitors of histone deacetylase 6 and the proteasome and agents that inhibit Hsp70 function.
  • Hsp90 plays a unique antiapoptotic role in small cell lung cancer cells, so that Hsp90 inhibition results in substantial cell death in both chemosensitive and chemoresistant small cell lung cancer cell lines.
  • Clinically, the geldanamycin compounds are the most mature, with manageable toxic effects.
  • The available data suggest that Hsp90 inhibitors should be evaluated in multiple lung cancer subsets.


8. Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, Bokemeyer C: Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res; 2003 Feb;9(2):767-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular determinants of treatment response in human germ cell tumors.
  • PURPOSE: Germ cell tumors (GCTs) are highly sensitive to cisplatin-based chemotherapy.
  • This feature is unexplained, as is the intrinsic chemotherapy resistance of mature teratomas and the resistant phenotype of a minority of refractory GCTs.
  • Various cellular pathways may influence the efficacy of chemotherapy.
  • EXPERIMENTAL DESIGN: We investigated proteins involved in regulation of apoptosis (p53, BAX, BCL-2, and BCL-X(L)), cell cycle control [p21 and retinoblastoma protein (RB)], and drug export and inactivation [P-glycoprotein, multidrug resistance-associated protein (MRP) 1, MRP2, breast cancer resistance protein, lung resistance protein, metallothionein, and glutathione S-transferase pi] immunohistochemically in samples of unselected GCT patients (n = 20), patients with advanced metastatic disease in continuous remission after first-line chemotherapy (n = 12), and chemotherapy-refractory patients (n = 24).
  • Mature teratoma components (n = 10) within tumor samples from all groups were analyzed separately.
  • RESULTS: Invasive GCTs of all groups showed a correlation between wild-type p53 and apoptotic index (r(s) = 0.66; P < 0.001).
  • No significant differences among the three patient groups were identified regarding any of the investigated parameters (all Ps were >0.08), even though only individual samples from chemotherapy-resistant cases showed a strong staining for MRP2 and GSTpi.
  • In contrast to other components, mature teratomas showed an intense p21 and RB staining and were mostly positive for MRP2, lung resistance protein, and GSTpi.
  • These findings suggest a preference for apoptosis over cell cycle arrest after up-regulation of p53.
  • None of the examined parameters offers a general explanation for the chemotherapy-resistant phenotype of refractory tumors.
  • The up-regulation of various factors interfering with chemotherapy efficacy and ability for a p21-induced cell cycle arrest may explain the intrinsic chemotherapy resistance of mature teratomas.
  • [MeSH-major] Germinoma / genetics. Germinoma / therapy. Testicular Neoplasms / genetics
  • [MeSH-minor] Adult. Antigens, Neoplasm / analysis. Apoptosis. Disease-Free Survival. Humans. Immunohistochemistry. Male. Middle Aged. Seminoma / genetics. Seminoma / mortality. Seminoma / pathology. Seminoma / therapy. Treatment Outcome


9. Saglam A, Hayran M, Uner AH: Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas. APMIS; 2008 Sep;116(9):791-800
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of multidrug resistance proteins in mature T/NK-cell lymphomas.
  • Multidrug resistance (MDR) is defined as resistance of tumor cells to a wide spectrum of structurally and functionally unrelated drugs.
  • One of the most important mechanisms in mediating MDR is that involving cellular drug efflux transporters.
  • Drug resistance is a common and formidable obstacle to therapy in mature T/NK-cell lymphomas and the MDR phenotype is thought to be one of the contributing mechanisms.
  • In this study we assessed the immunohistochemical expression of P-gp (P-glycoprotein), MRP-1 (multidrug resistance associated protein 1), BCRP (breast cancer resistance protein) and LRP (lung resistance protein) in 45 mature T/NK-cell lymphomas diagnosed at our hospital.
  • These findings show that our T/NK-cell lymphoma cases display high frequency of MDR protein expression.
  • [MeSH-major] ATP Binding Cassette Transporter, Sub-Family B / biosynthesis. ATP-Binding Cassette Transporters / biosynthesis. Lymphoma, Extranodal NK-T-Cell / metabolism. Multidrug Resistance-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Vault Ribonucleoprotein Particles / biosynthesis
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Adult. Aged. Aged, 80 and over. Child. Drug Resistance, Neoplasm. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024599.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family B; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


10. Girard N, Mornex F, Douillard JY, Bossard N, Quoix E, Beckendorf V, Grunenwald D, Amour E, Milleron B: Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial. Lung Cancer; 2010 Jul;69(1):86-93
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
  • Locally advanced non-small cell lung cancers share a risk of both local and systemic recurrence and justifies a therapeutic strategy combining focal and systemic treatment.
  • In resectable stage IIIA-N2 tumors, peri-operative chemotherapy significantly increases survival rates.
  • Chemoradiotherapy, which is the standard treatment of non-resectable locally advanced tumors, may have a role as an induction treatment to reduce locoregional recurrence rates.
  • In the present phase II trial, we aimed at comparing standard induction chemotherapy (arm A: cisplatin and gemcitabine) with 2 different regimens of induction chemoradiotherapy (total dose: 46 Gy) including third-generation cytotoxic agents (arm B: cisplatin and vinorelbine; arm C: carboplatin and paclitaxel) in patients with resectable stage IIIA-N2 NSCLC, using feasibility of the whole strategy, including surgery, as a primary endpoint.
  • Response rate was significantly higher after induction chemoradiotherapy vs. chemotherapy (87% vs. 57%, p=0.049).
  • The feasibility rate of the proposed therapeutic strategy was 89% for the whole cohort, 93% in arm A (induction chemotherapy with cisplatin and gemcitabine), 88% in arm B (induction chemoradiotherapy with cisplatin and vinorelbine), and 87% in arm C (induction chemoradiotherapy with carboplatin and paclitaxel) (p=0.857).
  • Induction chemoradiotherapy with modern treatment regimens is highly feasible and may show promises in the current and future developments of multimodal therapeutic strategies in locally advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Paclitaxel / administration & dosage. Survival Analysis. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19879013.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


11. Adelstein DJ, Rice TW, Rybicki LA, Greskovich JF Jr, Ciezki JP, Carroll MA, DeCamp MM: Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer. Lung Cancer; 2002 May;36(2):167-74
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accelerated hyperfractionated radiation, concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer.
  • The low surgical cure rate in patients with stage III non-small cell lung cancer has prompted an exploration of multimodality treatment strategies.
  • Mature results are presented from a phase II trial of accelerated hyperfractionated radiation therapy, concurrent paclitaxel/cisplatin chemotherapy and surgery for these patients.
  • Between 1994 and 1997, 45 patients with surgically demonstrated stage III non-small cell lung cancer underwent induction treatment with a 96 h continuous cisplatin infusion (20 mg/m(2) per day) and a 24 h infusion of paclitaxel (175 mg/m(2)) given concurrently with accelerated hyperfractionated radiation therapy (1.5 Gy twice daily) to a total dose of 30 Gy.
  • Induction was completed in ten treatment (12 total) days.
  • Surgical resection was scheduled 4 weeks later with a second identical course of chemoradiotherapy given 4-6 weeks post-operatively, to a total radiation dose of 60-63 Gy.
  • This short-course of paclitaxel and cisplatin chemotherapy and concurrent accelerated fractionation radiation is tolerable despite significant myelosuppression.
  • Distant metastases are the major cause of treatment failure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / therapy. Dose Fractionation. Lung Neoplasms / therapy. Thoracotomy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Survival Rate. Treatment Outcome


12. Eberhardt W, Bildat S, Korfee S, Stamatis G: Preoperative treatment strategies in stage III non-small cell lung cancer. Lung Cancer; 2001 Sep;33 Suppl 1:S51-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative treatment strategies in stage III non-small cell lung cancer.
  • Recent experience has emphasized the need to include systemic chemotherapy in combined-modality management of locally advanced non-small cell lung cancer stage III.
  • If definitive surgery is planned in these situations, preoperative application of drugs-induction chemotherapy-has many advantages in comparison to postoperative delivery.
  • Patients' compliance to treatment, achievable dose intensities of drugs, possible locoregional downstaging, and frequent postoperative problems following complex resections are some of the arguments favouring preoperative chemotherapy.
  • Early inclusion of radiotherapy prior to definitive resection may help to improve preoperative downstaging.
  • Besides available mature phase-II data, phase-III results from ongoing randomized trials are lacking to define the overall value of such a complex approach.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Clinical Trials as Topic. Humans. Neoplasm Staging. Preoperative Care / methods. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11576708.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Ireland
  •  go-up   go-down


13. Marisavljevic D, Markovic O, Cemerkic-Martinovic V, Ponomarev D: Plasmacytoma of the lung: an indolent disease resistant to conventional myeloma treatment: report of a case. Med Oncol; 2005;22(2):207-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmacytoma of the lung: an indolent disease resistant to conventional myeloma treatment: report of a case.
  • Solitary lung plasmacytoma is a rare form of plasma cell tumors.
  • Percutaneous transthoracic lung biopsy demonstrated a tumor-cell population consisting of mature plasma cells, proplasmacytes, and rare plasmablasts.
  • Radiotherapy and chemotherapy with alkylating agents were ineffective.
  • Some pathogenetic aspects of tumor resistance to conventional myeloma treatment in this case are discussed.
  • [MeSH-major] Drug Resistance, Neoplasm. Lung Neoplasms / diagnosis. Multiple Myeloma / drug therapy. Plasmacytoma / diagnosis


14. Bradley JD, Paulus R, Graham MV, Ettinger DS, Johnstone DW, Pilepich MV, Machtay M, Komaki R, Atkins J, Curran WJ, Radiation Therapy Oncology Group: Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. J Clin Oncol; 2005 May 20;23(15):3480-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
  • PURPOSE: To determine the overall survival, progression-free survival, and toxicity associated with concurrent paclitaxel/carboplatin and thoracic radiotherapy for completely resected patients with stage II and IIIA non-small-cell lung cancer (NSCLC).
  • Concurrent thoracic radiotherapy at 50.4 Gy in 28 fractions for 6 weeks (1.8 Gy/d, 5 days/wk) was given during cycles 1 and 2.
  • A boost of 10.8 Gy in six fractions was given for extracapsular nodal extension or T3 lesions.
  • RESULTS: Treatment compliance was acceptable, with 93% compliance for radiation therapy and 86% for chemotherapy completion.
  • The median overall survival time was 56.3 months, with 1-, 2-, and 3-year survival rates of 86%, 70%, and 61%, respectively.
  • CONCLUSION: The mature results of this trial suggest an improved overall and progression-free survival in this group of resected NSCLC patients, compared with previously reported trials.
  • A phase III trial comparing this treatment regimen with standard therapy seems warranted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / pathology. Lung Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Pneumonectomy / methods. Postoperative Care / methods. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908657.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


15. Nishida T, Nishiyama N, Inoue K, Kawata Y, Ichikawa T, Tsukioka T, Wakasa T, Wakasa K, Suehiro S: Successful resection of massively enlarged residual pulmonary metastases from a nonseminomatous germ cell testicular tumor. Osaka City Med J; 2006 Dec;52(2):87-92
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful resection of massively enlarged residual pulmonary metastases from a nonseminomatous germ cell testicular tumor.
  • A 25-year-old man was referred to our hospital in June 2000 for treatment of massive enlargement of residual pulmonary metastases from a nonseminomatous germ cell testicular tumor.
  • He had undergone right orchiectomy followed by cisplatin-based combination chemotherapy 7 years ago.
  • Chest radiography and computed tomography showed complete opacification of the left hemithorax with mediastinal shift to the right, and two smaller nodules in the right lung.
  • After salvage chemotherapy, elevated serum alpha-fetoprotein concentrations decreased to the normal range.
  • Postoperative pathologic examination disclosed metastatic germ cell tumors composed of mature teratoma.
  • When technically possible, resection of even massive pulmonary metastases after a favorable response to chemotherapy for a nonseminomatous germ cell tumor, can provide pathologic assessment of the response and offer patients a chance of long-term survival.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm, Residual

  • Genetic Alliance. consumer health - Nonseminomatous germ cell tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330397.001).
  • [ISSN] 0030-6096
  • [Journal-full-title] Osaka city medical journal
  • [ISO-abbreviation] Osaka City Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M: Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta; 2006 Jan;1765(1):25-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy.
  • Endocan, previously called endothelial cell specific molecule-1, is a soluble proteoglycan of 50 kDa, constituted of a mature polypeptide of 165 amino acids and a single dermatan sulphate chain covalently linked to the serine residue at position 137.
  • Experimental evidence is accumulating that implicates endocan as a key player in the regulation of major processes such as cell adhesion, in inflammatory disorders and tumor progression.
  • Endocan is clearly overexpressed in human tumors, with elevated serum levels being observed in late-stage lung cancer patients, as measured by enzyme-linked immunoassay, and with its overexpression in experimental tumors being evident by immunohistochemistry.
  • Recently, the mRNA levels of endocan have also been recognized as being one of the most significant molecular signatures of a bad prognosis in several types of cancer including lung cancer.
  • Collectively, these results suggest that endocan could be a biomarker for both inflammatory disorders and tumor progression as well as a validated therapeutic target in cancer.
  • On the basis of the recent successes of immunotherapeutic approaches in cancer, the preclinical data on endocan suggests that an antibody raised against the protein core of endocan could be a promising cancer therapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Biomarkers, Tumor / metabolism. Drug Delivery Systems. Endothelial Cells / metabolism. Neoplasm Proteins / metabolism. Proteoglycans / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Cell Transformation, Neoplastic / drug effects. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Molecular Sequence Data. Protein Conformation. Transcription, Genetic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168566.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / ESM1 protein, human; 0 / Neoplasm Proteins; 0 / Proteoglycans
  • [Number-of-references] 93
  •  go-up   go-down


17. de Figueiredo-Pontes LL, Pintão MC, Oliveira LC, Dalmazzo LF, Jácomo RH, Garcia AB, Falcão RP, Rego EM: Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom; 2008 May;74(3):163-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
  • BACKGROUND: The most primitive leukemic precursor in acute myeloid leukemia (AML) is thought to be the leukemic stem cell (LSC), which retains the properties of self-renewal and high proliferative capacity and quiescence of the hematopoietic stem cell.
  • LSC seems to be immunophenotypically distinct and more resistant to chemotherapy than the more committed blasts.
  • Considering that the multidrug resistance (MDR) constitutive expression may be a barrier to therapy in AML, we have investigated whether various MDR transporters were differentially expressed at the protein level by different leukemic subsets.
  • METHODS: The relative expression of the drug-efflux pumps P-gp, MRP, LRP, and BCRP was evaluated by mean fluorescence index (MFI) and the Kolmogorov-Smirnov analysis (D values) in five leukemic subpopulations: CD34+CD38-CD123+ (LSCs), CD34+CD38+CD123-, CD34+CD38+CD123+, CD34+CD38+CD123-, and CD34- mature cells in 26 bone marrow samples of CD34+ AML cases.
  • Finally, the comparative analysis between LSC and the most mature subset (CD34-) revealed higher MRP and LRP and lower P-gp expression in the LSCs.
  • CONCLUSIONS: Considering the cellular heterogeneity of AML, the higher MDR transporters expression at the most immature, self-renewable, and quiescent LSC population reinforces that MDR is one of the mechanisms responsible for treatment failure.
  • [MeSH-major] ATP-Binding Cassette Transporters / metabolism. ATP-Binding Cassette, Sub-Family B, Member 1 / metabolism. Leukemia, Myeloid, Acute / metabolism. Multidrug Resistance-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Neoplastic Stem Cells / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] ATP Binding Cassette Transporter, Sub-Family G, Member 2. Biomarkers, Tumor / metabolism. Case-Control Studies. Cell Differentiation. Drug Resistance, Neoplasm. Flow Cytometry / methods. Humans

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Clinical Cytometry Society
  • (PMID = 18200595.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1; 0 / Biomarkers, Tumor; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; Y49M64GZ4Q / multidrug resistance-associated protein 1
  •  go-up   go-down


18. Yang GC, Yee HT, Wu CD, Aye LM, Chachoua A: TIA-1+ cytotoxic large T-cell lymphoma of the mediastinum: case report. Diagn Cytopathol; 2002 Mar;26(3):154-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TIA-1+ cytotoxic large T-cell lymphoma of the mediastinum: case report.
  • A 52-year-old previously healthy Caucasian woman presented with superior vena cava syndrome, secondary to compression of a bulky anterior mediastinal mass involving the right lung.
  • Fine-needle aspiration biopsy of the mediastinum yielded large epithelioid cells intermingled with small mature lymphocytes.
  • The patient responded well to six cycles of CHOP chemotherapy, followed by radiation with a total dose of 4140 cGy delivered to the mediastinum in 23 fractions.
  • To the best of our knowledge, this case may be the first report of cytotoxic large T-cell lymphoma of the mediastinum.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell, Peripheral / pathology. Mediastinal Neoplasms / pathology. Membrane Proteins / biosynthesis. Proteins. RNA-Binding Proteins / biosynthesis. T-Lymphocytes, Cytotoxic / pathology
  • [MeSH-minor] Biopsy, Needle. Cytoplasmic Granules / chemistry. Cytoplasmic Granules / metabolism. Cytoplasmic Granules / ultrastructure. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Poly(A)-Binding Proteins

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11892019.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


19. Dearnaley DP, Fossa SD, Kaye SB, Cullen MH, Harland SJ, Sokal MP, Graham JD, Roberts JT, Mead GM, Williams MV, Cook PA, Stenning SP, MRC Testicular Tumour Working Party: Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer; 2005 Jun 20;92(12):2107-13
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17).
  • Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT), but the known toxicities of etoposide, and the expansion of the HR group to any patient with vascular invasion (50% of patients), led the Medical Research Council to pilot the BOP regimen.
  • Primary outcome was relapse rate; quality of life, fertility, hearing and lung function were assessed pre- and post-treatment.
  • A total of 115 eligible patients were registered, all received two courses of chemotherapy.
  • As assessed by clinicians during treatment, complete (reversible) alopecia was present in 20% of patients; World Health Organization (WHO) grade 1/2 neurotoxicity was present in 41%/5% of patients during treatment and 22%/1% at 6 months.
  • However, 12% of patients reported 'quite a bit' or 'very much' pain/numbness/tingling in hands/feet 2 years after chemotherapy.
  • Mature follow-up confirms high efficacy for two courses of cisplatin-based adjuvant chemotherapy in HRCS1 NSGCT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Germinoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Humans. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Orchiectomy. Pilot Projects. Prospective Studies. Quality of Life. Toxicity Tests. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1996 Nov;74(9):1487-91 [8912550.001]
  • [Cites] Support Care Cancer. 1996 Mar;4(2):118-28 [8673349.001]
  • [Cites] J Urol. 1999 Apr;161(4):1148-52 [10081858.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1629-40 [11250991.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):871-7 [12610187.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1107-18 [12637478.001]
  • [Cites] Lancet. 1983 Apr 30;1(8331):948-51 [6188011.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):203-9 [6197154.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] Lancet. 1987 Aug 8;2(8554):294-8 [2886764.001]
  • [Cites] Ann Oncol. 1991 Mar;2(3):203-11 [1710482.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1762-8 [1403057.001]
  • [Cites] S Afr Med J. 1994 Sep;84(9):605-7 [7530863.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):441-8 [8636755.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1106-13 [8648364.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • (PMID = 15928672.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; COB protocol
  • [Other-IDs] NLM/ PMC2361823
  •  go-up   go-down


20. Lung HL, Ip WK, Wong CK, Mak NK, Chen ZY, Leung KN: Anti-proliferative and differentiation-inducing activities of the green tea catechin epigallocatechin-3-gallate (EGCG) on the human eosinophilic leukemia EoL-1 cell line. Life Sci; 2002 Dec 6;72(3):257-68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-proliferative and differentiation-inducing activities of the green tea catechin epigallocatechin-3-gallate (EGCG) on the human eosinophilic leukemia EoL-1 cell line.
  • A novel approach for the treatment of leukemia is the differentiation therapy in which immature leukemia cells are induced to attain a mature phenotype when exposed to differentiation inducers, either alone or in combinations with other chemotherapeutic or chemopreventive drugs.
  • Over the past decade, numerous studies indicated that green tea catechins (GTC) could suppress the growth and induce apoptosis on a number of human cancer cell lines.
  • In the present study, the effect of the major GTC epigallocatechin-3-gallate (EGCG) on the proliferation and differentiation of a human eosinophilc leukemic cell line, EoL-1, was examined.
  • On the other hand, EGCG at a concentration of 40 microM could trigger the EoL-1 cells to undergo morphological differentiation into mature eosinophil-like cells.
  • Taken together, our findings suggest that EGCG can exhibit anti-leukemic activity on a human eosinophilic cell line EoL-1 by suppressing the proliferation and by inducing the differentiation of the leukemia cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Catechin / analogs & derivatives. Catechin / pharmacology. Hypereosinophilic Syndrome / drug therapy. Ribonucleases
  • [MeSH-minor] Blood Proteins / biosynthesis. Blood Proteins / genetics. Cell Differentiation. Cell Division. Dose-Response Relationship, Drug. Eosinophil Granule Proteins. Eosinophil Peroxidase. Growth Inhibitors / pharmacology. Humans. Kinetics. Peroxidases / biosynthesis. Peroxidases / genetics. RNA, Neoplasm / biosynthesis. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12427485.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Blood Proteins; 0 / Eosinophil Granule Proteins; 0 / Growth Inhibitors; 0 / RNA, Neoplasm; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 1.11.1.- / Eosinophil Peroxidase; EC 1.11.1.- / Peroxidases; EC 3.1.- / Ribonucleases
  •  go-up   go-down


21. Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL, Andreeff M: The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res; 2007 May 1;67(9):4210-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We and others have reported that C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid (CDDO-Me) effectively inhibits the growth of multiple cancer cell types.
  • Our previous studies indicated that prolonged CDDO-Me treatment inactivated extracellular signal-regulated kinase signaling in acute myelogenous leukemia cells.
  • Whether treatment with CDDO-Me has an earlier effect on other proteins that are important for either signal transduction or oncogenesis is unknown.
  • Constitutively activated STAT3 was shown to up-regulate c-Myc in several types of cancer and has a feedback effect on Src and Akt.
  • To examine the effects of CDDO-Me on STAT3 signaling in breast cancer, we used the murine 4T1 breast tumor model, which is largely resistant to chemotherapy.
  • In vitro, after treatment of 4T1 cells with 500 nmol/L CDDO-Me for 2 h, we found (a) inactivation of STAT3, (b) inactivation of Src and Akt, (c) 4-fold reduction of c-Myc mRNA levels, (d) accumulation of cells in G(2)-M cell cycle phase, (e) abrogation of invasive growth of 4T1 cells, and (f) lack of apoptosis induction.
  • In in vivo studies, CDDO-Me completely eliminated 4T1 breast cancer growth and lung metastases induced by 4T1 cells in mice when treatment started 1 day after tumor implantation and significantly inhibited tumor growth when started after 5 days.
  • In vivo studies also indicated that splenic mature dendritic cells were restored after CDDO-Me treatment.
  • In summary, these data suggest that CDDO-Me may have therapeutic potential in breast cancer therapy, in part, through inactivation of STAT3.
  • [MeSH-major] Mammary Neoplasms, Experimental / drug therapy. Oleanolic Acid / analogs & derivatives. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Growth Processes / drug effects. Dendritic Cells / drug effects. Dendritic Cells / immunology. Female. Genetic Vectors / genetics. Lentivirus / genetics. Luciferases, Renilla. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness. Signal Transduction / drug effects. Spleen / cytology. Spleen / drug effects. Spleen / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2008 Jun 15;68(12):4958
  • (PMID = 17483332.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 P50 CA100632; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / P50 CA116199
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / Stat3 protein, mouse; 6SMK8R7TGJ / Oleanolic Acid; CEG1Q6OGU1 / methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate; EC 1.13.12.5 / Luciferases, Renilla
  •  go-up   go-down


22. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, New T, O'Toole K, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ: Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A; 2003 Jun 24;100(13):7785-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, VEGF is also a key mediator of endothelial-vascular mural cell interactions, a role that may contribute to the integrity of mature vessels in advanced tumors.
  • Here, we report that high-affinity blockade of VEGF, using the recently described VEGF-Trap, abolishes mature, preexisting vasculature in established xenografts.
  • Eradication of vasculature is followed by marked tumor regression, including regression of lung micrometastases.
  • Potent blockade of VEGF may provide a new therapeutic option for patients with bulky, metastatic cancers.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5012-6 [10519416.001]
  • [Cites] J Clin Invest. 1999 Jan;103(2):159-65 [9916127.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5209-18 [10537299.001]
  • [Cites] J Pediatr Surg. 2000 Jan;35(1):30-2; discussion 32-3 [10646769.001]
  • [Cites] Microvasc Res. 2000 May;59(3):368-76 [10792968.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13333-40 [7768934.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 2):H2547-62 [8997316.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15732-9 [10336473.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4605-10 [11274374.001]
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11399-404 [12177446.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8624-5 [12861079.001]
  • (PMID = 12805568.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA088951; United States / NCI NIH HHS / CA / 1R01-CA088951-01A1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Lectins; 0 / Lymphokines; 0 / Recombinant Fusion Proteins; 0 / VEGF-Trap fusion protein, recombinant; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ PMC164665
  •  go-up   go-down


23. Kinebuchi Y, Ogawa T, Kato H, Igawa Y, Nishizawa O, Miyagawa S: Testicular cancer with tumor thrombus extending to the inferior vena cava successfully removed using veno-venous bypass: a case report. Int J Urol; 2007 May;14(5):458-60
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 33-year-old man with a left testicular tumor was referred to Shinshu University Hospital for advanced therapy.
  • After orchidectomy, a diagnosis of embryonal carcinoma was made with a clinical stage of T1N2M1bS3, which has a poor prognosis, based on the International Germ Cell Cancer Collaborative Group consensus.
  • After eight courses of chemotherapy, the patient's tumor markers normalized and the lung metastases disappeared, but the RPLN and tumor thrombus remained.
  • The pathological examination of the thrombus revealed a mature teratoma.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / pathology. Neoplastic Cells, Circulating. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Anastomosis, Surgical / methods. Humans. Male. Neoplasm Invasiveness. Remission Induction. Renal Artery / surgery. Renal Veins / surgery. Vascular Surgical Procedures / methods

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511736.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


24. McKendrick JJ, Mead GM, Cowlishaw D: Multiple relapses of mature teratoma, germinal and non-germ cell cancer in a patient treated with chemotherapy for testicular non-seminomatous germ cell cancer. Clin Oncol (R Coll Radiol); 2003 May;15(3):128-31
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple relapses of mature teratoma, germinal and non-germ cell cancer in a patient treated with chemotherapy for testicular non-seminomatous germ cell cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Neoplasm Recurrence, Local. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / pathology. Peritoneal Neoplasms / secondary. Teratoma / drug therapy. Teratoma / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology
  • [MeSH-minor] Bleomycin / administration & dosage. Cisplatin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Middle Aged. Neoplasm Metastasis. Orchiectomy

  • Genetic Alliance. consumer health - Teratoma.
  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801050.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down






Advertisement